Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125592 | 0.76 | PARL (0.37) | PARLMGLL | |
| SCHEMBL13097808 | 0.74 | PARL (0.31) | PARL | |
| SCHEMBL27701407 | 0.72 | MGLL (0.33) | MGLL | |
| SCHEMBL34300 | 0.72 | MGLL (0.33) | MGLL | |
| SCHEMBL14501470 | 0.71 | — | — | |
| SCHEMBL14990605 | 0.71 | — | — | |
| SCHEMBL28635874 | 0.71 | MGLL (0.32) | MGLL | |
| SCHEMBL10792270 | 0.71 | PARL (0.36) | PARLMGLL | |
| Vinylsulfonic Acid SCHEMBL381843 | 0.70 | PSMB8 (0.31) | — | |
| SCHEMBL13759593 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124051-B2 | Peptide, oligonucleotide suppressor of antiapoptotic cellular defense and anti-tumor agent covalently attached to same carrier peptide via bi-functional water-soluble polymer, so there is simultaneous uptake of suppressor and anti-tumor agent by tumor cells | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20080280813-A1 | COMPLEX DRUG DELIVERY COMPOSITION AND METHOD FOR TREATING CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | KCNN3, KCNN2, KCNN1 | PARL 3135/4885MGLL 1502/4885 |
| US-20080280813-A1 | COMPLEX DRUG DELIVERY COMPOSITION AND METHOD FOR TREATING CANCER | BAX, BCL2, ANXA5 | PARL 4275/4885MGLL 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.